SCHEMBL14770595

SCHEMBL14770595

CCOc1ccc2[nH]c(C(C)c3ccc(OCc4cccnc4)cc3)nc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.44
DYRK1A Q13627 1/20 0.44
MEN1 O00255 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 2/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
DHODH Q02127 1/20 0.42
CYP19A1 P11511 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
FGFR1 P11362 1/20 0.39
GPR132 Q9UNW8 4/20 0.39
ACACB O00763 2/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770568 0.89 MEN1 (0.47) MEN1HTTKMT2AALDH1A1TP53
SCHEMBL12065258 0.89 DHODH (0.43) MAOADYRK1AMEN1HTTKMT2A
SCHEMBL14770580 0.84 FFAR1 (0.46) MAOAMEN1HTTKMT2AALDH1A1
SCHEMBL14770573 0.84 MEN1 (0.46) MAOAMEN1HTTKMT2ANPC1
SCHEMBL14770587 0.83 MEN1 (0.46) MAOAMEN1HTTKMT2APOLB
SCHEMBL14770571 0.83 KMT2A (0.46) MAOAMEN1HTTKMT2ATDP1
SCHEMBL14770579 0.82 CYP1A2 (0.46) MAOAMEN1HTTKMT2AALDH1A1
SCHEMBL14770605 0.81 MEN1 (0.46) MAOAMEN1HTTKMT2AALDH1A1
SCHEMBL14770548 0.80 FFAR1 (0.44) MEN1HTTKMT2AALDH1A1TP53
SCHEMBL14770535 0.80 MEN1 (0.53) MEN1HTTKMT2AALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MAOA 2082/4885DYRK1A 2352/4885MEN1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.